-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

Benzinga·10/08/2026 14:41:53
语音播报
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.